Literature DB >> 17448454

Establishing a neurological-psychiatric biobank: banking, informatics, ethics.

Maria J Molnar1, Peter Bencsik.   

Abstract

The recent development of genetic databases and biobanks in a number of countries reflects scientist's beliefs in the future health benefits to be derived from genetic research. The NEPSYBANK is a national program of the Hungarian Clinical Neurogenetic Society with comprehensive participation of the Neurology and Psychiatry Departments of Medical Universities and the National Institute of Psychiatry and Neurology. The NEPSYBANK forms a part of the national biobank project (www.biobank.hu). The goal is to establish nationwide collaboration and common biobanking standards on quality, access, and protection of integrity in the field of neurology and psychiatry. Biological materials and databases are already collected in stroke, epilepsy, multiple sclerosis, motoneuron diseases, dementia, movement disorders, schizophrenia, and alcohol addiction. In peripheral neuropathies, neuropathic pain syndromes, muscle diseases, migraine, myasthenia gravis, depression, panic disease, anxiety, autism, and software development is in progress. The resources have been expanded by continued prospective collection of samples and data and important bottlenecks in sample purification, sample retrieval, in protection of the integrity of the research participants, as well as in guaranteeing the security and confidentiality of the participant's information have been harmonized. The development of uniform consent management, comprehensive sample overview and quality standards for health care-related biobanking may provide a unique opportunity for Hungary in molecular clinically oriented research. The program is a diseased-based research biobank with comprehensive collection of phenotypic and environmental information as well as biobanking of DNA, RNA or buffy coat, plasma, and erythrocytes stored at -80 degrees C. The biobank has a neuropathological part as well: storing conventional pathology and biopsy specimens. The analytical and informational demands being created by biobanking requires a "connectivity of community" that has not traditionally been present in the life sciences. As you put more resources into something, your silos tend to become taller, and we need to avoid this. The life science and healthcare community should be ignored working in individual "silos."

Entities:  

Mesh:

Year:  2007        PMID: 17448454     DOI: 10.1016/j.cellimm.2007.02.013

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  9 in total

1.  [Biobanking and Biomolecular Resources Research Infrastructure (BBMRI). Implications for pathology].

Authors:  C Viertler; K Zatloukal
Journal:  Pathologe       Date:  2008-11       Impact factor: 1.011

2.  Design and establishment of a biobank in a multicenter prospective cohort study of elderly patients with venous thromboembolism (SWITCO65+).

Authors:  Marie Méan; Drahomir Aujesky; Bernhard Lämmle; Christiane Gerschheimer; Sven Trelle; Anne Angelillo-Scherrer
Journal:  J Thromb Thrombolysis       Date:  2013-11       Impact factor: 2.300

3.  Managing incidental findings and research results in genomic research involving biobanks and archived data sets.

Authors:  Susan M Wolf; Brittney N Crock; Brian Van Ness; Frances Lawrenz; Jeffrey P Kahn; Laura M Beskow; Mildred K Cho; Michael F Christman; Robert C Green; Ralph Hall; Judy Illes; Moira Keane; Bartha M Knoppers; Barbara A Koenig; Isaac S Kohane; Bonnie Leroy; Karen J Maschke; William McGeveran; Pilar Ossorio; Lisa S Parker; Gloria M Petersen; Henry S Richardson; Joan A Scott; Sharon F Terry; Benjamin S Wilfond; Wendy A Wolf
Journal:  Genet Med       Date:  2012-04       Impact factor: 8.822

Review 4.  Ethical aspects of human biobanks: a systematic review.

Authors:  Danijela Budimir; Ozren Polasek; Ana Marusić; Ivana Kolcić; Tatijana Zemunik; Vesna Boraska; Ana Jeroncić; Mladen Boban; Harry Campbell; Igor Rudan
Journal:  Croat Med J       Date:  2011-06       Impact factor: 1.351

5.  Biobank research and ethics: the problem of informed consent in Polish biobanks.

Authors:  Jakub Pawlikowski; Jarosław Sak; Krzysztof Marczewski
Journal:  Arch Med Sci       Date:  2011-11-08       Impact factor: 3.318

6.  MSTO1 is a cytoplasmic pro-mitochondrial fusion protein, whose mutation induces myopathy and ataxia in humans.

Authors:  Aniko Gal; Peter Balicza; David Weaver; Shamim Naghdi; Suresh K Joseph; Péter Várnai; Tibor Gyuris; Attila Horváth; Laszlo Nagy; Erin L Seifert; Maria Judit Molnar; György Hajnóczky
Journal:  EMBO Mol Med       Date:  2017-07       Impact factor: 12.137

7.  The Role of Genetic Testing in the Clinical Practice and Research of Early-Onset Parkinsonian Disorders in a Hungarian Cohort: Increasing Challenge in Genetic Counselling, Improving Chances in Stratification for Clinical Trials.

Authors:  Anett Illés; Dóra Csabán; Zoltán Grosz; Péter Balicza; András Gézsi; Viktor Molnár; Renáta Bencsik; Anikó Gál; Péter Klivényi; Maria Judit Molnar
Journal:  Front Genet       Date:  2019-10-31       Impact factor: 4.599

8.  Genetic landscape of early-onset dementia in Hungary.

Authors:  Dora Csaban; Anett Illes; Toth-Bencsik Renata; Peter Balicza; Klara Pentelenyi; Viktor Molnar; Andras Gezsi; Zoltan Grosz; Aniko Gal; Tibor Kovacs; Peter Klivenyi; Maria Judit Molnar
Journal:  Neurol Sci       Date:  2022-06-25       Impact factor: 3.830

Review 9.  Recent advances in genetic predisposition of myasthenia gravis.

Authors:  Zoi Zagoriti; Manousos E Kambouris; George P Patrinos; Socrates J Tzartos; Konstantinos Poulas
Journal:  Biomed Res Int       Date:  2013-11-05       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.